Wallenstam AB Series B (0R7Y)
London Exchange · UK · prices in SEK · close of 16 Oct 2026
Key indicators
| Last close | SEK 37.34 |
|---|---|
| 52-week range | 34.04 – 45.59 |
| Return, 1 month / 3 months | −1.8% / −10.0% |
| Return, 1 year / 3 years | −11.8% / +8.5% |
| Trend | Below its 200-day average |
| RSI (14) | 55 |
| Volatility (1 year) | 21.5% |
| Worst drawdown (1 year) | -24.4% |
| Average daily value traded | 3.48M SEK |
| Dividend yield | 1.5% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Wallenstam AB is a Swedish property company based in Gothenburg. It owns and manages residential rental apartments along with commercial premises such as offices, shops and industrial space, and it also develops and constructs new homes and buildings. Its customers are mainly tenants in its residential and commercial properties, concentrated in Swedish cities including Gothenburg and Stockholm. The company manages its properties over the long term and handles its own project development and construction work.
Wallenstam AB Series B trades under the code 0R7Y on the London Exchange in UK, with its price quoted in Swedish kronor (SEK). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Wallenstam AB Series B (0R7Y) trades on the London Exchange in UK. It last closed at SEK 37.34 on 16 October 2026.
Its price-based Market X-Ray is 51 out of 100 (a fair price profile), ranking 2,013 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 11.8% and over the last three months it fell 10.0%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 37 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -7.5% | ||
| From 52-week high | -17.7% | ||
| Momentum | 28 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -10.0% | ||
| 6-month return | -11.6% | ||
| 12-month return, skipping the last month | -10.1% | ||
| Stability (higher is calmer) | 73 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 21.5% | ||
| Worst drawdown, 1 year (smaller is calmer) | -24.4% | ||
| Liquidity | 64 · Fair | Moderate trading activity. | |
| Average daily value traded | 3.48M SEK | ||
| Zero-volume days | 0.0% | ||
| Income | 69 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 1.5% | ||
| Years with dividends | 6 |
Strengths
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
Returns
| 1 week | +8.0% |
|---|---|
| 1 month | −1.8% |
| 3 months | −10.0% |
| 6 months | −11.6% |
| 1 year | −11.8% |
| 3 years | +8.5% |
| 5 years | – |
Signals
| 50-day / 200-day average | 38.74 / 40.36 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.62 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 29 Apr 2026 | SEK 0.3000 |
| 31 Oct 2025 | SEK 0.2500 |
| 30 Apr 2025 | SEK 0.2500 |
| 28 Oct 2024 | SEK 0.2500 |
| 26 Apr 2024 | SEK 0.2500 |
| 31 Oct 2023 | SEK 0.3000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.